The Odisha government has unveiled a new Pharmaceutical and Medical Devices Policy‑2025, targeting investments of Rs 25,000 crore and the creation of one lakh jobs by 2030 as it seeks to position the state as an eastern hub for drug and medical device manufacturing. Chief Minister Mohan Charan Majhi launched the policy at the Odisha Pharma Summit 2025 in the presence of Industries Minister Sampad Chandra Swain and senior government officials.
Industries Department Additional Chief Secretary Hemant Sharma said the policy is aimed at tapping a major opportunity in medical devices, noting that India currently imports about 85 per cent of its requirements in this segment. With a large number of pharmaceutical and medical device units expected to come up nationally over the next five years, Odisha is seeking to secure a meaningful share of this growth, he added.
Under the policy, the state is offering a 50 per cent subsidy on concessional land cost for units employing more than 200 Odisha‑domiciled skilled workers, alongside a 30 per cent capital subsidy on eligible plant and machinery, disbursed at up to 6 per cent per annum for five years without any upper cap. In addition, a 25 per cent subsidy capped at Rs 1 crore will be provided for dedicated power infrastructure to support new projects.
Officials said the new policy is expected to catalyse investments of Rs 25,000 crore and generate direct and indirect employment for around one lakh people by 2030, with Memorandums of Understanding worth Rs 5,000 crore signed on the day of the launch itself. The policy aims to attract anchor investors while also fostering local entrepreneurship and MSME growth across both skilled and semi‑skilled segments.
Anchored in the state’s Industrial Policy Resolution (IPR) 2022, which identifies pharmaceuticals, bulk drugs and medical devices as thrust sectors, the policy focuses on infrastructure readiness, research excellence, industry‑academia collaboration for skilling and a facilitative regulatory environment. As part of this, the government plans to develop an Odisha Pharma Park and an Odisha MedTech Park, each spread over more than 200 acres, as integrated good manufacturing practices (GMP)‑ready clusters.
The policy combines support on land, finance, skilled workforce, regulatory facilitation and R&D to attract investments across active pharmaceutical ingredients (APIs), formulations, vaccines, diagnostics, imaging, implants and wearables, positioning Odisha as a competitive and sustainable manufacturing and innovation destination. It covers a broad spectrum of products, including APIs, bulk drugs, formulations, vaccines, biologicals, biosimilars, veterinary drugs, animal vaccines, nutraceuticals and cosmetics classified as drugs, as well as in‑vitro diagnostics, implants, surgical consumables, instruments, medical wearables, digital health devices and device software.
